METHODS: Search for compatible units was conducted by the American Rare Donor Program (ARDP) with no leads. After chemotherapy induction and despite erythropoiesis stimulating agent administration, the patient\'s hemoglobin continued to trend down to a nadir of 2.8 g/dL. Here we report transfusion of incompatible pRBC to this patient with critically symptomatic anemia. HBOC-201 (Hemopure) was obtained and administered under an emergency compassionate/expanded access designation from the Food and Drug Administration (FDA) under an emergency Investigational New Drug (IND) application.
CONCLUSIONS: Overall difficulties in this case included the challenge of finding compatible units, dilemma of transfusing incompatible units in a patient with severe anemia and obtaining alternatives to blood products. This case report demonstrates the successful use of HBOC-21 in treating life-threatening anemia.
方法:由美国稀有捐赠者计划(ARDP)进行无导线的兼容单位搜索。化疗诱导后,尽管施用红细胞生成刺激剂,患者的血红蛋白继续下降至最低点2.8g/dL。在这里,我们报告了向患有严重症状性贫血的患者输注不相容的pRBC。HBOC-201(Hemopure)是在紧急研究新药(IND)申请下,根据食品和药物管理局(FDA)的紧急同情/扩展访问指定获得和管理的。
结论:这种情况下的总体困难包括寻找兼容单位的挑战,在患有严重贫血的患者中输注不相容单位并获得血液制品替代品的困境。该病例报告证明了HBOC-21在治疗危及生命的贫血中的成功使用。